• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc. (Amendment)

    2/9/23 11:32:50 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SUPN alert in real time by email
    SC 13G/A 1 tv01991-supernuspharmaceutic.htm SCHEDULE 13G/A supernuspharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 5)*

    Name of issuer:  Supernus Pharmaceuticals Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  868459108

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  868459108

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    34,447

    7.  SOLE DISPOSITIVE POWER

    5,703,846

    8.  SHARED DISPOSITIVE POWER

    86,114

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,789,960

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.71%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Supernus Pharmaceuticals Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    9715 Key West Avenue
    Rockville, MD 20850

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    868459108

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $SUPN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SUPN

    DatePrice TargetRatingAnalyst
    7/30/2025$42.00Neutral → Overweight
    Cantor Fitzgerald
    2/19/2025$57.00 → $36.00Overweight → Neutral
    Cantor Fitzgerald
    1/6/2025$57.00Overweight
    Cantor Fitzgerald
    9/11/2024$41.00 → $36.00Overweight → Neutral
    Piper Sandler
    1/3/2023$44.00 → $45.00Buy
    Jefferies
    12/1/2021$40.00 → $44.00Buy
    Jefferies
    More analyst ratings

    $SUPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sensenig Bethany sold $226,840 worth of shares (5,369 units at $42.25), closing all direct ownership in the company (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    8/18/25 4:31:18 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hudson Frederick M. sold $315,133 worth of shares (7,457 units at $42.26), decreasing direct ownership by 14% to 46,307 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    8/18/25 4:28:44 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sr. VP of IP, CSO Bhatt Padmanabh P.

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    8/8/25 4:43:33 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Supernus Pharma upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Supernus Pharma from Neutral to Overweight and set a new price target of $42.00

    7/30/25 7:19:36 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharma downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $57.00 previously

    2/19/25 7:05:55 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Supernus Pharma with a new price target

    Cantor Fitzgerald initiated coverage of Supernus Pharma with a rating of Overweight and set a new price target of $57.00

    1/6/25 8:47:11 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    SEC Filings

    View All

    SEC Form 10-Q filed by Supernus Pharmaceuticals Inc.

    10-Q - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    8/5/25 4:24:41 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    8/5/25 4:18:57 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    8/1/25 6:04:57 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Supernus Announces Second Quarter 2025 Financial Results

    Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, respectively. Net sales of GOCOVRI® increased 16% in the second quarter of 2025, compared to the same period in 2024. Net sales of GOCOVRI of $36.7 million and $67.4 million in the second quarter and first six months of 2025, respectively. ONAPGO™ (apomorphine hydrochloride) launched in April 2025.Total revenues were $165.5 million and $315.3 million for the three and six months ended June 30, 2025, respectively, compared to $168.3 million and $312.0 million, respectively, for the s

    8/5/25 4:05:40 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

    ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ("Supernus") today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage"). "Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026." Compelling Strategic Rationale Strengthens psychi

    7/31/25 8:44:03 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

    ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supernus' proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ:SAGE) ("Sage"), expired at 11:59 p.m. Eastern Time on July 25, 2025. On June 13, 2025, Supernus and Sage, entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among Supernus, Sage and Saphire, Inc., a Delaware corporation and a wholly owned subsidiary of Supernus ("Purchaser")

    7/28/25 8:25:15 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Financials

    Live finance-specific insights

    View All

    Supernus Announces Second Quarter 2025 Financial Results

    Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, respectively. Net sales of GOCOVRI® increased 16% in the second quarter of 2025, compared to the same period in 2024. Net sales of GOCOVRI of $36.7 million and $67.4 million in the second quarter and first six months of 2025, respectively. ONAPGO™ (apomorphine hydrochloride) launched in April 2025.Total revenues were $165.5 million and $315.3 million for the three and six months ended June 30, 2025, respectively, compared to $168.3 million and $312.0 million, respectively, for the s

    8/5/25 4:05:40 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

    ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ("Supernus") today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage"). "Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026." Compelling Strategic Rationale Strengthens psychi

    7/31/25 8:44:03 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

    ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the second quarter 2025 financial and business results on Tuesday, August 5, 2025 at 4:30 p.m. ET. Following management's prepared remarks and discussion of business results, the ca

    7/22/25 4:30:19 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

    SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    11/14/24 5:14:42 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

    SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    11/1/24 4:35:56 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Supernus Pharmaceuticals Inc.

    SC 13G - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    10/31/24 11:55:00 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Leadership Updates

    Live Leadership Updates

    View All

    Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

    Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2 ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3 Glazer, who has always been outspoken about his mental health struggles, wa

    10/16/23 5:34:21 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care